InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,708.75
(
-0.93%
)
US TECH 100
19,200.40
(
-1.65%
)
Dow Jones
42,156.97
(
-0.41%
)
Brent Oil
74.83
(
0.55%
)
Bitcoin
61,489.63
(
1.08%
)
Post# of 253265
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120523
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Friday, 06/28/2024 12:46:33 PM

Friday, June 28, 2024 12:46:33 PM

Post# of 253265
ALMS IPOs 15.1M* shares @$16.00:

https://www.globenewswire.com/news-release/2024/06/28/2905639/0/en/Alumis-Announces-Pricing-of-Initial-Public-Offering.html

Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases.

…Alumis’ most advanced product candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of TYK2 that is currently being evaluated for the treatment of patients with moderate-to-severe plaque psoriasis and systemic lupus erythematosus. Alumis is also developing A-005, a CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases.

*Assuming exercise of underwriter’s option.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up